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OBJECTIVES: International pharmacoeconomic studies
should comply with methodological guidelines, which
state that cost data must be country-speciﬁc and clearly
referenced. This study aims to identify the different
requirements in each country and report costing sources
that can be used. It also establishes common requirements
between countries, and identiﬁcation and data type issues
in each country. METHOD: Seven European countries
were chosen for analysis. Literature was analysed to
review current pharmacoeconomic guidelines, costing
requirements and perspective that should be adopted.
Using the review results, and researchers with pharma-
coeconomic expertise and local country knowledge, rele-
vant country costing sources were found. Each source was
reviewed and data extracted into an international costing
sources database. Particular attention was given to the
reliability of the source, price year, frequency of updates,
type and level of costing, allowing meaningful compar-
isons between countries. RESULTS: Even though an
important issue in international economic studies is cross-
country cost analyses, there was very little published lit-
erature showing combined synthesis of costing sources.
International guidelines tended to recommend the use of
direct costs, particularly from the perspective of the gov-
ernment or third party payer. Main internationally re-
cognised medical direct costs include medical visits,
pharmaceuticals and hospitalisations, but between coun-
tries, the costing units may differ. The level of costing
varied among countries and several reported hospitalisa-
tions costs are at DRG (Diagnosis Related Group) or spe-
cialty levels, for example. The frequency of price updates
was not similar among countries, generally from one to
three years. CONCLUSION: The database was popu-
lated following pharmacoeconomic guidelines, ensuring
relevance, accuracy and quality of cost data collection.
These factors are essential in conducting economic eval-
uations. This summarising of data allows an easy way of
identifying what is available in each country and what
methods should be adopted when performing pharma-
coeconomic cost analyses. With research sponsors often
looking towards international economic models and
analyses, such timely information is important.
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UNCERTAINTY AND VALUE OF INFORMATION
IN RAPID ECONOMIC EVALUATIONS
Gonzalez-Perez JG
University of Aberdeen, Aberdeen, United Kingdom
Health care decision makers often have to make their
decisions quickly and using information that is less than
perfect. The provision of information is challenging as
short timescales preclude primary data collection. As a
result reliance is place on modelling exercises informed
by systematic review. OBJECTIVE: Using value of infor-
mation techniques may help to quantify the extent of
uncertainty and identify whether it is cost-effective to
gather more information. Uncertainty in modelling is out-
lined here in the frame of the rapid assessment of the cost-
effectiveness of home haemodialysis for end stage renal
failure (ESRF). METHODS: A net beneﬁt approach is
adopted to compute value of gathering more information.
Evaluation was hampered as data on the costs and rela-
tive effectiveness of ESRF treatments are limited. The
short time frame available for the study caused further
uncertainty, resulting in two treatment options being
treated as absorbing states (as was death) in the Markov
model. Generalisable data were also limited. For example,
cost data, although detailed and comprehensive, related
to one centre and no utility data were available for the
setting of interest. Such challenges were overcome by 
discussing the framing of the research question with the
decision-maker and undertaking thorough sensitivity
analysis. RESULTS: An initial deterministic model pro-
vided sufﬁcient information for decision. A subsequent
probabilistic analysis broadly supported the decision
(although its results were unavailable at the time to deci-
sion-makers). The initial decision did not explicitly con-
sider the value of improvements to the evidence base
although this was facilitated by the probabilistic analysis.
CONCLUSON: Value of information analysis can help
to measure uncertainty surrounding results based on
imperfect information and may become a useful addition
both to those undertaking economic evaluations and deci-
sion makers themselves.
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OBJECTIVES: To present a protocol of a medicoeco-
nomic study which compares—in terms of medical effec-
tiveness, satisfaction and costs—outpatient management
of infantile bronchiolitis by paediatricians vs homeo-
pathic and allopathic GPs in France. METHODS: We
performed a bibliographic review and consulted clinical,
statistical, and health-economics experts to deﬁne and
validate the protocol. RESULTS: A prospective, “real-
world”, observational study is to be carried out. Two
independent epidemiological/economic observatories are
to be set up with 130GPs and 80 paediatricians recruited
by sample-drawing. Each doctor is to include 4 “patients
aged between 3 and 24-months, consulting for their ﬁrst
bout of acute bronchiolitis since birth, who have not yet
received treatment and who do not require immediate
hospitalisation”. The patients are to be monitored for a
period of 6 months. The diagnostic criteria are: dry cough
and/or tachypnea and/or intercostal retraction and/or
wheezing. Throughout the entire monitoring period,
medical effectiveness is to be assessed in terms of: 1)
number, severity and duration of bouts; 2) complications;
and 3) persistence of bronchial obstruction. Parent and
doctor satisfaction is to be assessed using a 4-level Likert
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scale. Direct medical costs are divided into outpatient and
hospital costs. Outpatient costs (medical visits, medica-
tion, additional tests, physiotherapy sessions) are to be
assessed using French public prices and Social Security
tariffs. Hospital costs are to be assessed using the PMSI
database. Indirect costs are to be assessed in terms of 
the number and duration of sick-leaves. Costs are to be
assessed from the perspectives of society, patient and
Social Security. The comparability of the 2 patient groups
are to be statistically analysed before comparing results.
CONCLUSION: Given the public-health problem caused
by epidemic infantile bronchiolitis each year in France,
the results of this pragmatic medicoeconomic study will
aid public policy makers and practitioners in determin-
ing the most cost-effective Health care management
strategies.
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OBJECTIVE: To show that indirect intervention costs
can be crucial for the results of large-scale prevention pro-
grams. METHODS: We estimated the indirect costs of the
Dutch meningococcal serogroup C conjugate immuniza-
tion program of all persons aged 14 months to 18 years
that ran from June 2002 until January 2003. Using the
friction cost method, we measured the indirect interven-
tion costs caused by additional health visits due to 
the catch-up immunization program and side effects of
immunization as well as the indirect savings due to
averted cases of meningococcal disease and its complica-
tions. For valuing the work-loss of parents accompany-
ing younger children (less than 15 years) we used the
average labor costs per employed parent that was com-
puted by weighting the age- and sex speciﬁc labor costs
of employees with the age- and sex speciﬁc probabilities
of being a parent. For valuing the work-loss of persons
aged 15 years or older, we used the age- and sex-speciﬁc
labor costs per capita. RESULTS: The immunization
program caused indirect intervention costs of €17.14
million. As the indirect savings due to prevented cases of
meningococcal disease were only €0.75 million, the net
indirect costs were €16.39 million. Including the indirect
costs increases the cost-effectiveness ratio of the immu-
nization program from about €13,200 per life year gained
to about €17,700 per life year gained. These results are
sensitive to the work-time loss per vaccination, the way
children were called in for vaccination, i.e. whether by
birth-cohort or by ZIP-code, and the approach for indi-
rect cost measurement. CONCLUSIONS: Indirect inter-
vention costs can be substantial and should always be
measured. Failing to do so cannot only lead to mislead-
ing results but also to higher than necessary indirect costs
as the decision maker might not take them into account
when planning the program setup.
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OBJECTIVE: While Type 1 Diabetes only affects 5–10%
of the 16 million people with diabetes, it accounts for
about 30% of the total costs. The primary purpose of this
presentation is to review the literature and identify cost-
effective treatments for Type I Diabetes. METHOD: A
search was conducted using Medline and other interna-
tional publications and resources. Articles were retrieved
and reviewed with results synthesized and summarized by
the cost effectiveness of the intervention or treatment
method. RESULTS: Studies on the cost-effectiveness of
treatment for Type 1 Diabetes proved difﬁcult to locate.
Economic information regarding treatment varied greatly
across studies, but generally demonstrated a cost beneﬁt.
For interventions of diabetic retinopathy, studies using
simulated populations showed a cost-savings for panreti-
nal photocoagulation for proliferative diabetic retinopa-
thy and focal photocoagulation for macular edema. A
similar cost-saving was found in pre-conception care with
a cost beneﬁt ratio of the care program being 5.19,
meaning for every $1 spent on the program, there would
be a net savings of $5.19. While the rate of costs or
savings were varied, interventions for diabetic nephropa-
thy and glycemic control were clearly cost effective. Two
interventions assessed did not demonstrate cost-
effectiveness: 1) the self-management training interven-
tion which showed only potential cost-effective results,
and 2) the self-monitoring of blood glucose (SMBG)
which displayed unclear results. CONCLUSION: This
review shows that most of the available studies on cost-
effectiveness of Type 1 Diabetes deal with interventions
geared to prevent or arrest the progression of complica-
tions. The most accessible ones are studies on diabetic
retinopathy and nephropathy. Studies that address cost-
effectiveness of self-management and SMBG are difﬁcult
to ﬁnd. For a chronic disease such as Type 1 Diabetes,
non-empirical study data is more common, and the source
of cost-effectiveness data (for modeling, etc.) has also
been derived mostly from non-empirical sources.
